Companion Diagnostics Market

1. Executive Summary
    1.1. Key Market Insights

2. Introduction            
    2.1. Study Objectives
    2.2. Market Definition
           2.2.1. Market Covered
           2.2.2. Regional Coverage
           2.2.3. Study Years & Currency
    2.3. Market Stakeholders
    2.4. Key Questions this Study will Answer
    2.5. GMI Research’s Approach & Methodology
           2.5.1. Research Data
           2.5.2. Primary Data
           2.5.3. Demand Side and Supply Side Analysis
           2.5.4. Market Size Estimation
           2.5.5. Research Assumptions

3. Global Companion Diagnostics Market- Overview            
    3.1. Introduction
    3.2. Market Segmentation
    3.3. Value Chain Analysis
    3.4. Market Drivers
    3.5. Market Restraints
    3.6. Market Trends

4. Global Companion Diagnostics Market Revenue Forecast till 2030     

5. Global Companion Diagnostics Market by Offering Revenue Forecast till 2030            
    5.1. Solution
    5.2. Service

6. Global Companion Diagnostics Market by Technology Revenue Forecast till 2030            
    6.1. PCR
    6.2. NGS
    6.3. IHC
    6.4. FISH
    6.5. Others

7. Global Companion Diagnostics Market by Disease Type Revenue Forecast till 2030            
    7.1. Breast Cancer
    7.2. NSCLC
    7.3. Melanoma
    7.4. Colorectal
    7.5. Others

8. Global Companion Diagnostics Market by End-Use Revenue Forecast till 2030            
    8.1. Hospitals
    8.2. Pathology and Diagnostic Labs
    8.3. Academic Medical Center
    8.4. Others

9. Global Companion Diagnostics Market by Region Forecast till 2030
    9.1. North America Companion Diagnostics Market Revenue Forecast till 2030
    (Option 1: As a part of the free 25% customization)
           9.1.1. North America Companion Diagnostics Market by Offering
                     9.1.1.1. Solution
                     9.1.1.2. Service
           9.1.2. North America Companion Diagnostics Market by Technology
                     9.1.2.1. PCR
                     9.1.2.2. NGS
                     9.1.2.3. IHC
                     9.1.2.4. FISH
                     9.1.2.5. Others
           9.1.3. North America Companion Diagnostics Market by Disease Type
                     9.1.3.1. Breast Cancer
                     9.1.3.2. NSCLC
                     9.1.3.3. Melanoma
                     9.1.3.4. Colorectal
                     9.1.3.5. Others
           9.1.4. North America Companion Diagnostics Market by End-Use
                     9.1.4.1. Hospitals
                     9.1.4.2. Pathology and Diagnostic Labs
                     9.1.4.3. Academic Medical Center
                     9.1.4.4. Others
           9.1.5. US Companion Diagnostics Market All-Up
           9.1.6. Canada Companion Diagnostics Market All-Up
    9.2. Europe Companion Diagnostics Market Revenue Forecast till 2030
    (Option 2: As a part of the free 25% customization)
           9.2.1. Europe Companion Diagnostics Market by Offering
                     9.2.1.1. Solution
                     9.2.1.2. Service
           9.2.2. Europe Companion Diagnostics Market by Technology
                     9.2.2.1. PCR
                     9.2.2.2. NGS
                     9.2.2.3. IHC
                     9.2.2.4. FISH
                     9.2.2.5. Others
           9.2.3. Europe Companion Diagnostics Market by Disease Type
                     9.2.3.1. Breast Cancer
                     9.2.3.2. NSCLC
                     9.2.3.3. Melanoma
                     9.2.3.4. Colorectal
                     9.2.3.5. Others
           9.2.4. Europe Companion Diagnostics Market by End-Use
                     9.2.4.1. Hospitals
                     9.2.4.2. Pathology and Diagnostic Labs
                     9.2.4.3. Academic Medical Center
                     9.2.4.4. Others
           9.2.5. UK Companion Diagnostics Market All-Up
           9.2.6. Germany Companion Diagnostics Market All-Up
           9.2.7. France Companion Diagnostics Market All-Up
           9.2.8. Spain Companion Diagnostics Market All-Up
           9.2.9. Rest of Europe Companion Diagnostics Market All-Up
    9.3. Asia-Pacific Companion Diagnostics Market Revenue Forecast till 2030
    (Option 3: As a part of the free 25% customization) 
           9.3.1. Asia-Pacific Companion Diagnostics Market by Offering
                     9.3.1.1. Solution
                     9.3.1.2. Service
           9.3.2. Asia-Pacific Companion Diagnostics Market by Technology
                     9.3.2.1. PCR
                     9.3.2.2. NGS
                     9.3.2.3. IHC
                     9.3.2.4. FISH
                     9.3.2.5. Others
           9.3.3. Asia-Pacific Companion Diagnostics Market by Disease Type
                     9.3.3.1. Breast Cancer
                     9.3.3.2. NSCLC
                     9.3.3.3. Melanoma
                     9.3.3.4. Colorectal
                     9.3.3.5. Others
           9.3.4. Asia-Pacific Companion Diagnostics Market by End-Use
                     9.3.4.1. Hospitals
                     9.3.4.2. Pathology and Diagnostic Labs
                     9.3.4.3. Academic Medical Center
                     9.3.4.4. Others
           9.3.5. China Companion Diagnostics Market All-Up
           9.3.6. India Companion Diagnostics Market All-Up
           9.3.7. Japan Companion Diagnostics Market All-Up
           9.3.8. Rest of APAC Companion Diagnostics Market All-Up
    9.4. RoW Companion Diagnostics Market Revenue Forecast till 2030
    (Option 4: As a part of the free 25% customization)  
           9.4.1. RoW Companion Diagnostics Market by Offering
                     9.4.1.1. Solution
                     9.4.1.2. Service
           9.4.2. RoW Companion Diagnostics Market by Technology
                     9.4.2.1. PCR
                     9.4.2.2. NGS
                     9.4.2.3. IHC
                     9.4.2.4. FISH
                     9.4.2.5. Others
           9.4.3. RoW Companion Diagnostics Market by Disease Type
                     9.4.3.1. Breast Cancer
                     9.4.3.2. NSCLC
                     9.4.3.3. Melanoma
                     9.4.3.4. Colorectal
                     9.4.3.5. Others
           9.4.4. RoW Companion Diagnostics Market by End-Use
                     9.4.4.1. Hospitals
                     9.4.4.2. Pathology and Diagnostic Labs
                     9.4.4.3. Academic Medical Center
                     9.4.4.4. Others
           9.4.5. Brazil Companion Diagnostics Market All-Up
           9.4.6. South Africa Companion Diagnostics Market All-Up
           9.4.7. Saudi Arabia Companion Diagnostics Market All-Up
           9.4.8. UAE Companion Diagnostics Market All-Up
           9.4.9. Rest of world (remaining countries of the LAMEA region) Companion Diagnostics Market All-Up

10. Competitive Landscape Analysis
    10.1. Porter’s Five Forces Analysis
    10.2. Industry – Competitive Landscape
    10.3. Market Presence (Intensity Mapping)
    10.4. Key Strategic Market Developments

11. Company Profiles (Option 5: Free 25% Customization - Profiles of 5 Additional Companies of your Choice)
    11.1. Agilent Technologies, Inc.
            11.1.1. Company Overview
            11.1.2. Key Executives
            11.1.3. Footprint & Employee Strength
            11.1.4. Product Offerings
            11.1.5. Financials
            11.1.6. Key Company Developments
    11.2. Illumina, Inc.
            11.2.1. Company Overview
            11.2.2. Key Executives
            11.2.3. Footprint & Employee Strength
            11.2.4. Product Offerings
            11.2.5. Financials
            11.2.6. Key Company Developments
    11.3. QIAGEN
            11.3.1. Company Overview
            11.3.2. Key Executives
            11.3.3. Footprint & Employee Strength
            11.3.4. Product Offerings
            11.3.5. Financials
            11.3.6. Key Company Developments
    11.4. Thermo Fisher Scientific, Inc.
            11.4.1. Company Overview
            11.4.2. Key Executives
            11.4.3. Footprint & Employee Strength
            11.4.4. Product Offerings
            11.4.5. Financials
            11.4.6. Key Company Developments
    11.5. F. Hoffmann-La Roche Ltd.
            11.5.1. Company Overview
            11.5.2. Key Executives
            11.5.3. Footprint & Employee Strength
            11.5.4. Product Offerings
            11.5.5. Financials
            11.5.6. Key Company Developments
    11.6. ARUP Laboratories
            11.6.1. Company Overview
            11.6.2. Key Executives
            11.6.3. Footprint & Employee Strength
            11.6.4. Product Offerings
            11.6.5. Financials
            11.6.6. Key Company Developments
    11.7. Abbott
            11.7.1. Company Overview
            11.7.2. Key Executives
            11.7.3. Footprint & Employee Strength
            11.7.4. Product Offerings
            11.7.5. Financials
            11.7.6. Key Company Developments
    11.8. BioMérieux SA
            11.8.1. Company Overview
            11.8.2. Key Executives
            11.8.3. Footprint & Employee Strength
            11.8.4. Product Offerings
            11.8.5. Financials
            11.8.6. Key Company Developments
    11.9. Invivoscribe, Inc.
            11.9.1. Company Overview
            11.9.2. Key Executives
            11.9.3. Footprint & Employee Strength
            11.9.4. Product Offerings
            11.9.5. Financials
            11.9.6. Key Company Developments
    11.10. Myriad Genetics, Inc.
            11.10.1. Company Overview
            11.10.2. Key Executives
            11.10.3. Footprint & Employee Strength
            11.10.4. Product Offerings
            11.10.5. Financials
            11.10.6. Key Company Developments

12. About GMI Research

*Details on Financials might not be available in case of unlisted/private companies.

*The list of companies is based on preliminary research in this sample report, the companies in the final report may change based on research findings.